Thermo Fisher Scientific (TMO)
Health Care · Life Sciences Tools & Diagnostics
Global leader in life sciences tools, diagnostics, and laboratory services supporting research, diagnostics, and bioproduction across pharma, biotech, and clinical markets.
What Thermo Fisher Scientific does
Thermo Fisher Scientific is a diversified life sciences company that develops and manufactures products, services, and software for research, diagnostics, and bioproduction. The company operates across multiple segments serving pharmaceutical, biotechnology, healthcare, and academic customers globally. Key business lines include analytical instruments, reagents, consumables, laboratory software, clinical diagnostics, and contract research and manufacturing services. The company also provides specialized services including genomics analysis, protein purification, cell therapy manufacturing, and pharmaceutical contract manufacturing and development.
Themes: ["Bioproduction and biotech manufacturing","Drug discovery and development","Genomics and sequencing","Clinical diagnostics","Contract manufacturing (CDMO)","Lab automation and data management","Cell therapy and regenerative medicine","Life sciences research tools","Pharma supply chain services","Precision medicine"]
Fundamentals
- Price$524.71 as of 2026-07-09 close
- Market cap$193.1B as of 2026-07-10
- 1-year return+25.0% as of 2026-07-09 close
- P/E28.21 as of 2026-07-10
- Net margin+15.2% as of 2026-07-10
- Gross margin+40.9% as of 2026-07-10
- ROE+13.2% as of 2026-07-10
- Debt / equity0.83 as of 2026-07-10
- Revenue growth (YoY)+5.4% as of 2026-07-10
- Revenue CAGR (3y)-0.3% SEC XBRL
- Beta0.86 as of 2026-07-10
Dividend: yield +0.4%; 5-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["International revenue exposure and currency exchange risk: International markets contribute substantially to revenues; fluctuations in exchange rates and foreign currency movements could adversely affect reported revenues, profitability, and customer demand.","Market cyclicality and economic sensitivity: Certain businesses operate in cyclical industries; declines in served markets, economic instability, inflation, and supply chain disruptions could reduce demand, increase order cancellations, and pressure pricing.","Geopolitical and regulatory risks: Tariffs, trade barriers, sanctions, Chinese local supplier requirements, and changing trade relationships create supply chain volatility and operational complexity in emerging markets."]
Competitors & peers
- Danaher Corporation (DHR)
- Agilent Technologies (A)
- PerkinElmer (PKI)
- Bio-Rad Laboratories (BIO)
- Illumina (ILMN)
- Abbott Diagnostics
- Roche Diagnostics
- Bruker Corporation (BRKR)
- Waters Corporation (WAT)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.